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Secretion of Recombinant Human fibrinogen by the Murine
Mammary Gland
Abstract
Transgenic animals secreting individual chains and assembled fibrinogen were produced to
evaluate the capacity of the mammary gland for maximizing assembly, glycosylation and
secretion of recombinant human fibrinogen (rhfib). Transgenes were constructed from the 4.1 kbp
murine Whey Acidic Protein promoter (mWAP) and the three cDNAs coding for the Aα,Bβ and
γ fibrinogen chains. Transgenic mice secreted fully assembled fibrinogen into milk at
concentrations between 10 and 200 μg/ml, with total secretion of subunits approaching 700 μ
g/ml in milk. Partially purified fibrinogen was shown to form a visible and stable clot after
treatment with human thrombin and factor XIII. The level of assembled fibrinogen was
proportional to the lowest amount of subunit produced where both the Bβ and γ chains were rate
limiting. Both the Bβ and γ chains were glycosylated when co-expressed and the degree of
saccharide maturation was dependent on expression level, with processing preferred for γ chains
over chains. Also, the subunit complexes Aαγ2, γ2 and the individual subunits Aα, Bβ and γ were
found as secretion products. When the Bβ was secreted individually, the glycosylation profile of
the molecule was of a mature complex saccharide indicating recognition of the molecule by the
glycosylation pathway without association with other fibrinogen chains. To date secretion of Bβ
chain has been not observed in any cell type, suggesting that the secretion pathway in mammary
epithelia is less restrictive than that occurring in hepatocytes and other cells previously used to
study fibrinogen assembly.
Key words: mammary gland expression, recombinant human fibrinogen, transgenic mouse WAP
promoter.
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1.0 Introduction
Fibrinogen (AαBβγ)2 is a complex plasma glyco-protein that participates in the blood
coagulation cascade. It is synthesized in the liver as a dimeric molecule that is comprised of two
subunits linked by three disulfide bonds, each containing three polypeptide chains for a combined
molecular weight of 340 kDa. The three polypeptides, Aα (66 kDa), Bβ (54 kDa), and γ (48 kDa)
are linked by disulfide rings to form a coiled spiral of α-helices (Doolittle, 1984). N-linked
polysaccharides are present on the Bβ and γ chains of both subunits and glycosylations of these
chains are required for fibrin polymerization by thrombin. Applications for fibrin sealant have
been developed including use as a hemostatic agent and as a carrier matrix for the delivery of
drugs and biologics (Greco et al., 1991; Alving et al., 1995; MacPhee et al., 1996a, b; Lasa et al.,
1996). Thus, there is considerable economic incentive to develop recombinant versions of human
fibrinogen (rhfib), which would be specific-pathogen-free and cost eﬀectively abundant
(Velander et al., 1996).
The cDNA sequences coding for each fibrinogen chain have been cloned (Rixon et al.,
1983; Chung et al., 1983a, b), and the synthesis and secretion of fibrinogen have been extensively
studied in cultured hepatocytes and a variety of transfected cell types (Yu et al., 1984;
Danishefsky et al., 1990, Roy et al., 1990, 1991; Hartwig & Danishefsky, 1991; Huang et al.,
1993, 1996: Zhang & Redman, 1996). Pulse chase experiments in hepatocytes have determined
that the rates of new chain synthesis for each peptide are identical (Roy et al., 1994), and newly
synthesized Bβ-chain associates rapidly with already present intracellular pools of Aα and γ
chains, suggesting β-chain incorporation in chain assembly is the rate limiting step in fibrinogen
production (Yu et al., 1984). Regulation of the intracellular pools of free chains appears to be
modulated by retrotranslocation, where association of the free chains with translocon component
Sec61b leads to their eventual degradation in the proteasome (Hui & Redman, 2001). Secretion
into cell culture media is not limited to fully assembled fibrinogen, but includes free chains of Aα
and γ , Aα – γ complex and Aα Bβ γ half molecules (Hartwig & Danishefsky, 1991; Roy et al.,
1991). In contrast, secretion of significant amounts of Bβ -chain has not been observed by any
cell type and is thought to be retained and degraded when the other fibrinogen chains are not
present (Danishefsky et al., 1990).

Currently, fully assembled fibrinogen has been secreted into the milk of both mice and
sheep carrying the genomic fibrinogen coding sequences linked to the ovine β lactoglobulin
(oBLG) milk protein promoter (Prunkard et al., 1996; Cottingham et al., 1997). The
concentration of fibrinogen subunits in mouse milk, as determined by reduced Western analysis,
varied from 30 to 2000 μg/ml depending upon the transgenic line studied. It was also reported
that when all three subunits were expressed in a balanced ratio, 100% of the subunit chains were
incorporated into fully assembled fibrinogen. The glycosylation status of the Bβ and γ subunits
was not reported, but purified rhfib was shown to undergo thrombin induced polymerization and
γ-chain cross-linking by Factor XIII.
The objective of this study was to evaluate the capacity of the mammary gland for
secreting each separate fibrinogen subunit and to then characterize the maturity of the
glycosylation. We confirm the assembly of functional fibrinogen using the whey acidic protein
promoter to direct synthesis of each of the subunit chains and then assess the secretion and
glycosylation of individual chains, along with the glycosylation state of both the Bβ and γ
subunits of secreted assembled fibrinogen. In the context of the normal physiology of the
mammary epithelial cell as it occurs in a transgenic mouse, we show for the first time that the Bβ
chain having mature glycosylation can be eﬃciently secreted by a mammalian cell.

2.0 Materials and methods
2.1 Transgene construction
The 4.1 kbp murine whey acidic protein (mWAP) promoter was obtained by digestion of
p227.6 (American Red Cross, Rockville, MD) with NotI, KpnI and HindIII. The fragment
containing the 30 UTR and pUC NotI + vector was obtained by partial digestion of pUCWAP5
(Virginia Polytechnic Institute and State University, Blacksburg, VA) with NotI and a full
digestion with KpnI. The resulting fragments were then ligated to make the cassette vector
pUCWAP6. After size and restriction site verification (NotI and NotI/ KpnI digest), large scale
purification was performed. The cDNAs for cloning were obtained from Susan Lord (University
of North Carolina, Chapel Hill, NC) and end modified by polymerase chain reaction (PCR) to
produce KpnI sites directly 5’and 3’ of the coding start and stop sequences, respectively. The
vector pUCWAP6 was linearized with KpnI, combined with each cDNA and ligated. The
following restriction endonuclease enzymes were used for verifying the cDNA orientation:
pUCWAP6FibAα1/PstI yielding expected fragments of 2.1, 2.4 and 5.9 kbp;

Figure 1. Transgene design and Southern analysis of established transgenic lines. The three fibrinogen
transgenes, WAP6FibAa, WAP6FiBβ and WAP6Fib1 were produced by introducing the cDNA for each
chain between the 4.1 kbp promoter and 1.6 kbp30UTR elements of mWAP, upper panel. These constructs,
in turn, were used to produce founder animals through microinjection. Oﬀspring from these founders were
screened by Southern analysis with one example from each line presented in lower panel. N.T. = nontransgenic,°C= band produced by endogenous WAP. Bands Aa,Bβ

and γ

are produced by their

corresponding transgenic constructs.

pUCWAP6FiBβ b1/BamHI yielding fragments of 750 bp and 9.5 kbp; and pUCWAP6Fibc1/PstI
yielding fragments of 980 bp, 3.2 and 5.8 kbp (Figure 1). After verifying the sequences across the
promoter/cDNA and cDNA/3’ UTR junctions, plasmids were cut with NotI/PvuI and constructs
purified by ultracentrifugation through a NaCl step gradient (7.5, 12.5, 17.5, and 20%) by the
method of Fink (1991). Construct DNA was diluted to 5 μg/ml in microinjection buﬀer (10 mM

Tris–HCl, 0.1 mM EDTA) to produce monogenic lines or mixed in equal molar amounts for comicroinjection at a final concentration of 5 μg/ml.
2.2 Generation of transgenic animals
Generation of transgenic mice followed the general method of Hogan et al. (1986) for
embryo collection and Canseco et al. (1994) for embryo microinjection. Experiments on animals
in this study were approved by the University Animal Care Committee and followed the National
Research Council’s guide for the care and use of laboratory animals. Briefly, female CD-1 mice
approximately 25–29 days of age were superovulated with intraperitoneal injections of 10 IU
Pregnant Equine Serum Gonadotropin followed by 5 IU human Chorionic Gonadotropin (hCG)
48 h later and placed with males. Zygotes from mated mice were collected in M2 medium 21 h
after hCG and microinjected with 1–4 pl of DNA solution at 5 μg/ml. Surviving embryos were
transferred to oviducts of pseudopregnant females (30–100 embryos per recipient) with the
number transferred reflective of survivability studies done in culture for each preparation of
DNA.
2.3 Identification of transgenic animals
DNA samples were isolated from murine tail biopsies by the method of Velander et al.
(1992) and subjected to PCR analysis by general method of Saiki et al. (1989). PCR positive
animals were further screened by Southern analysis. Southern analysis was performed on 10 lgof
tail biopsy DNA digested with endonuclease PstI and probed with a radiolabelled [a32P]dATPPstI/KpnI promoter fragment. Digestion of trigenic mouse DNA with endonuclease
PstI, which cuts each construct at the same site in the promoter region but varies the 3’ cut,
produced fragment sizes of 4.3 kbp for WAP6FiBβ b1, 3.0 kbp for WAP6Fibc1 and 2.2 for
WAP6FibA1 (Figure 1). The WAP probe hybridized with each fragment identically and also
hybridized with a 5.0 kbp fragment produced by the endogenous WAP gene. Relative copy
numbers for each construct within a given line were determined by comparing each lane’s
internal WAP control (2 copies) to the signal intensity produced for each construct. Signal
intensity (by volume determination) from autoradiographic film was performed using a
densitometer and the corresponding Image Quant software (Molecular Dynamics, Sunnyvale,
CA).

2.4 Collection and processing of mouse milk
Milk from transgenic and control mice was directly collected into 1.7 ml centrifuge tubes
by vacuum aspiration, with 200 μl of milk removed, added to 200 μl of milk buﬀer (50 mM Tris
and 200 mM EDTA, pH 8.5) and frozen at -90 °C. Milk samples were defatted by centrifugation
at 15,000 x g in a bench top centrifuge for 20 min at 4°C. After skimming, the resulting clarified
milk (prepared whey) was stored at- 90 °C until analysis.
2.5 Western analysis
Gel electrophoresis was carried out on polyacrylamide gradient gels from Novex (San
Diego, CA), 8–16% for reducing conditions and 4–12% for non-reducing conditions using Tris–
glycine buﬀer (25 mM Tris, 0.1% SDS and 200 mM glycine). Unless otherwise noted, 1 μl of
prepared whey was loaded per sample and electrophoresis was conducted until the 7.0 kDa
marker reached the end of the gel or ran oﬀ. Gels were transferred to PVDF membranes (BioRad)
in Towbin buﬀer (10% methanol, 200 mM glycine, 25 mM Tris, 0.1% SDS) at 4°C, at 200 mA
overnight using a BioRad Trans-blot cell. Membranes were blocked using TBSTC (20 mM Tris,
50 mM NaCl, 0.05% Tween 20, 0.5% bovine casein, pH 7.2) for 3 h to overnight with gentle
agitation. Blots were probed with a primary antibody for 1–3 h at 37 °C with gentle agitation.
Primary antibodies and the concentrations used were: polyclonal raBβ it anti-Aα-chain (AB784),
anti-Bβ -chain (AB785), anti-γ-chain (AB786) from Chemicon International Inc. (Temecula,
CA) and used at 1:5000; ADI (1:1000), raBβ it polyclonal for all three fibrinogen chains
(American Diagnostic Inc.); Y18 mAb (1:1000), mouse monoclonal for Aα-chain; Shainoﬀ
mAb(1:300), mouse monoclonal for Bβ chain; and NS15 pAb (1:150), raBβ it polyclonal for γchain . The Y18 mAb, Shainoﬀ mAb and NS15 pAb were kindly provided by Susan Lord
(University of North Carolina; Chapel Hill, NC). After incubation, the blots were rinsed in
deionized water for 5 min. Horseradish peroxidase conjugated antibodies used include raBβ it
anti-hfib (Dako A/S, Denmark), goat anti-raBβ it IgG and goat anti-mouse IgG (Sigma A9169,
and A4416), respectively. After incubation the blots were rinsed three times in deionized water
and developed according to manufacturer’s instructions for 1–10 min using a metal enhanced
Diaminobenzidine kit (Pierce, Rockford, IL). Deglycosylation experiments were performed using
Endoglycosidase-H or PNGase (New England Biolabs, Beverly, MA) with 150 U/mg of protein,
per manufacturer’s instructions. Samples were separated by electrophoresis and blotted as above

and probed with either AB785 or AB786 (1:5000) polyclonal raBβ it antibody (Chemicon
International, Inc.). Hfib standard was provided by the American Red Cross.
2.6 Detection of rhfib by ELISA
The level of rhfib in the prepared whey samples was determined by polyclonal ELISA.
Plasma derived hfib was used as a reference standard. Immulon II microtiter plates were coated
with 5 mg/ml of raBβ it anti-hfib diluted in 0.1 M NaHCO3, pH 9.6. Wells were washed with
TBST and 100 ng of hfib reference, transgenic prepared whey or nontransgenic prepared whey
dilutions were added to the plate and incubated for 30min at 37°C. Wells were washed with TBS/
Tween and 1:10,000 diluted horseradish peroxidase-conjugated raBβ it anti-hfib (Dako,
Carpinteria, CA) was added to all wells and incubated for 30min at 37°C. Upon completion of
incubation the wells were washed and 100 llof OPD (O-phenylenediamine; ABβ ott Labs, ABβ
ott Park, IL) solution was added to each well. The reaction was stopped after 3–4 min by the
addition of 100 llof3N H2SO4 and the absorbance was measured at 490 nm.

2.7 Partial purification of the transgenic fibrinogen
A whey pool sample was prepared from mouse milk collected from diﬀerent trigenic
fibrinogen mice. Frozen EDTA-treated prepared whey samples (derived as described above) were
defrosted at 10oC and mixed in a vortex mixer to help resolubilize cryoprecipitated fibrinogen.
Three ml of each prepared whey pool was applied to a 2 ml Fast-flow DEAE-Sepharose
chromatography column, the column was then washed with 125 mM NaCl, 50 mM Tris and 200
mM EDTA, pH 8.5 buﬀer, and then eluted with 250 mM NaCl, 50 mM Tris and 200 mM EDTA,
pH 8.5 buﬀer. The column eluate was concentrated to 0.5 ml by lyophilization and rendered with
8 mM zinc acetate, pH 7. The mixture was centrifuged at 10,000 x g for 3 min at room
temperature and the supernatant and pellets were evaluated by SDS-PAGE and Western Blot

analysis. Both the supernatant and pellets of the control mouse and transgenic whey purification
products were retained for clotting analysis. Pellets were reconstituted in 50 mM Tris, 100 mM
CaCl, pH 8.5 buﬀer at room temperature.

2.8 Functional activity of transgenic fibrinogen
The clotting activity of reference and purification products derived from control whey and
transgenic samples was evaluated by the visual formation of a clot precipitate by the addition of
200 U/ml bovine thrombin. Reference treatment samples consisting of 300 μg/ml hfib (gift of the
American Red Cross) dissolved in 50 mM Tris, 100 mM CaCl, 7 and 8 mM zinc acetate, pH 8.5
buﬀer. A similarly treated control whey superna- tant product was also evaluated. The thrombin
reaction mixtures were allowed to incubate for 15 min at 21°C. All samples were centrifuged for
2 min at 10,000 x g and examined for a clot. The samples containing evidence of a clot
precipitate were then resuspended and adjusted to 200 μg/ml Factor XIII derived from human
plasma(gift of the American Red Cross).The samples were again incubated for 15 min at 21C and
then centrifuged at 10,000 x g and then treated with 10 M Urea, 1% sodium dodecyl sulfate, 1%
mercaptoethanol by gentle heating for 2 min at 100 °C in a capped 1 ml Eppendorf tube. The
dissolved clot–pellet solutions were evaluated by SDS-PAGE and Western analysis using
polyclonal anti-era against hfib γ-chain.
3.0 Results:
3.1 Expression of individual fibrinogen chains by the transgenic mammary gland.
Individual lines of transgenic mice were established by out breeding founder animals that
carried one of the mammary specific expression vectors WAP6FibAα1 WAP6FibBβ1 or
WAP6Fibγ1.Production efficiencies are summarized in Table 1 for each individual construct
where transgene integration and transmission fell in the typical range for transgenic mouse
production. Upon establishing lines for each construct Southern analysis was performed to judge
transmissible copy numbers for each line,where total transgene copies varied from 1 to greater
than 50 among the different lines (Table 2).Evaluation of individual fibrinogen chain expression
was conducted on prepared whey from naturally lactating females (minimum n=3) of a given
line during the course of lactation (days 5,10 ,15) and over successive lactations.Prepared whey
samples were subjected to Western analysis under reducing conditions and compared hfib
standards.

Only one line (43) of the generated WAP6FibAα1 mice produced a sufficient quantity of Aαchain under non-reducing conditions that migrated identical to

human standard(Figure

2a),suggesting this chain is properly processed and secreted in monomer form by memmary
ephithelia. In contrast to the Aα-chain and Bβ chain was not secreted in monomer form by
WAP6FibBβ1 mice and no chain complexes were detected under non reducing conditions using
several different antibodies .However ,secreted Bβ-chain was detected under reducing conditions
with mobility similar to hfib(figure 2b) in three of the six established lines. The Presence of this
band only under reducing conditions indicates that Bβ-chain is either secreted in association with
other proteins or secreted in a conformation that prevents epitope recognition by variety of
antibodies .Western analysis

of milk from WAP6Fibγ1 transgenic

mice under reducing

conditions produced a band which migrated identically to human standard (figure 2c ),suggesting
the γ-chain was able to be secreted into milk by the mammary epithelia of these animals. These
animals represented one of the two established lines.
3.2 Expression of rhfib and chain complexes by the transgenic animal mammary gland.
Transgenic mice carrying all three fibrinogen chain constructs were produced by comicroinjection of individual construct at an equal molar concentration. Overall nine triple
transgenic(WAP6FibT.C.) founder mice were generated

and upon breeding

with control

animals ,six lines of transgenic mice wee established. Since the three constructs were not
physically linked before microinjection the transgene locus for a given line may vary in
composition by the ratio and copy numbers of the gene constructs within the locus .Southern

analysis of each established line was performed to verify PCR results and to quantify the
number of transgenes within the integration site.The four bands produced by Sothern analysis of
a transgenic mouse DNA are indicated in figure 1.The fragment produced by the endogenous
WAP genes (~50 kbps) acts as amount of DNA loaded for gel electrophoresis,due to the presence
of endogenous WAP at two copies per diploid genome (GeneBank ,NIH).By comparing the
signal intensities for a given lane the relative copy numbers of each transgene within the
integration site were determined and presented in table 3.Variations of both the molecular ratio
of transgenes and number of copies present within the given locus were observed similar to that
previously reported when using three separate transgenes (Punkard etal.,1996)

Prepared milk samples from several animals of a given line over the course of first and
second lactation were subjected to ELISA to determine which lines were expressing rhfib, to
what level, and if expression was stable during the course of lactation. ELISA results identified
that three of the six trigenic lines secreted detectable amounts of rhfib and/or rhfib chain
complexes into their milk (Table 3). Upon analysis of these lines over the course of lactation,
variations in expression were observed. Previous research has indicated that murine WAP-based
transgenes are influenced by chromosomal DNA elements flanking the integration site by
modulating the hormonal response of the promoter elements (Burdon et al., 1991). In order to
verify that the lack of secreted individual chain and chain complexes is not due to the processing
activity of mammary epithelia, but instead due to promoter activity, we conducted Northern
analysis and have found a direct correlation between absence of mRNA and absence of protein.

Samples with the strongest ELISA signals were subjected to Western analysis in order to
determine if each chain was correctly processed and to identify the secretion products composing
the signal.

Prepared whey samples from the three expressing lines were subjected to Western
analysis under reducing conditions using a polyclonal 3 chain antibody (Figure 3b). All three
chains were detected in transgenic prepared whey with the migration of the rhfib Aαand Bβ
chains being identical to human standard (lane 1), but the γ-chain having a slightly faster
mobility. Also present are several higher molecular weight species which most likely represent
incomplete reduction and separation of fibrinogen and/or fibrinogen chain complexes, as these
are not found in non-transgenic prepared whey. In order to identify the degree of secreted subunit
assembly, identical samples were run under non-reducing conditions and probed with the same
ADI antibody, (Figure 3a). The antibody recognizes only a single band in the human standard
(lane 1), but also binds to mouse fibrinogen with a low aﬃnity in lane 2. Trigenic milk samples
have several bands present, indicating secretion of individual chains and/or chain complexes.
There are two prominent bands (Aαand AG) with apparent sizes of 66 and 135–150 kDa,
respectively, which correspond in molecular weight to Aachain monomers and an Aac2chain
complex. The monomer form is found secreted in all lines studied, suggesting its ability for free
secretion similar to monogenic a-chain mice. The Aαmonomer signal produced by prepared whey
from line 10 is more intense than that produced by milk from mice of line 37 and 21, but in
contrast, band AG is very weak in line 10 and very strong in the other two lines. It is important to
note the trans-gene ratio with this line where the a transgene ratio is higher than the other two

lines. Upon mRNA analysis by Northern a higher ratio of a message was observed in line 10 as
compared to the other lines, confirming the behavior of the integration site to be copy number
dependent as seen with other mWAP driven transgenes (Burdon et al., 1991). These observations
along with the absences of bands below 198 kDa in the non-transgenic whey sample indicate
individual chains and partial chain complexes can be secreted by the mammary gland. The other
minor bands

Figure 3. Western analysis of prepared whey from triple transgenic mice under reduced and nonreduced conditions. Upper panel, prepared whey from triple transgenic mice was separated by SDS-PAGE
under non-reducing (a) or reducing conditions (b) and probed with the ADI polyclonal antibody. Lane 1,
hfib 120 ng; lane 2, 1 ll of non-transgenic prepared whey; lane 3, 1 ll of line 37 prepared whey; lane 4, 1 ll
of prepared whey from line 37 homozygous animal; lane 5, 1 ll of line 21 prepared whey; and lane 6, 1 ll of
line 10 prepared whey. Lower panel, prepared whey from triple transgenic mice was separated by SDSPAGE under non-reducing conditions and probed by a chain specific antibody; Y18, Shainoﬀ, NC15 for
Aa,Bβ and°Cchains, respectively. Lane 1, 200 ng hfib; lane 2, 1 ll of non-transgenic prepared whey; lane 3,
1 ll of line 10 prepared whey; lane 4, 1 ll of line 21 prepared whey; and lane 5, 1 ll of line 37 prepared
whey.

Band

designations

are:

A,

fibrinogen

c immunoglobulin; and fib, assembled fibrinogen.

Aa-chain;

AG,

Aα °Ccomplex;

mIg,

mouse

present in the transgenic milk samples may be the association of free chains or chain complexes
with naturally occurring milk proteins such as the a caseins which are known to interact among
themselves via cystine bridging.
In order to identify whether the A band is free Aa-chain and the AG band contains the
Aasubunit, a non-reduced blot from trigenic lines was probed with a Aa-chain-specific
monoclonal antibody (Figure 3, lower panel). There are four major bands identified: Aα at~ 66
kDa, AG at ~130–150 kDa, mIg at 180 kDa and fib ~340 kDa. The concentration of the Aαband
is found most abundantly in the line 10 sample with lower levels found in samples from lines 21
and 37. In contrast, the AG band was found most intense in milk samples from line 21 and 37.
These observations indicate that free Aαhain is readily secreted by the mammary gland and a
higher molecular weight complex containing at least the Aα-subunit is also secreted under
conditions when all three chains are present. The mIg band produced in all mouse samples was
due to recognition of secreted IgG by the secondary conjugated antibody (A4416, anti-mouse)
used during blot development.
To evaluate whether Bβ -chain was being secreted by these mice as free chain or as a
complex, a blot using a monoclonal Bβ -subunit antibody was performed and is shown in Figure
3, lower panel. Only two significant bands were identified, the mIg band previous discussed and
the rhfib band migrating identically to the human standard. These observations indicate that the
β-chain is being produced at a level where it is incorporated into fully assembled rhfib. Since this
antibody does not crossreact with mouse fibrinogen, the relative amounts of rhfib secreted among
diﬀerent mice can be observed. To follow the pattern of secretion for the γ-chain and to rule out
the possibility that the AG band was not an oligomer of Aa-subunits, a c-subunit blot was
performed using a γ-chain specific polyclonal antibody (Figure 3, lower panel). Two bands were
produced: AG at 130–150 kDa and rhfib at 340 kDa. The fibrinogen band was found in all lines
and in the human standard. The AG band was not detected in line 10 milk, but was present in
milk samples from mice of line 21 and 37. Thus, the high molecular weight species that we have
observed does contain all of the fibrinogen subunits.
3.3 Glycosylation state of rhfib chains
The glycosylation state of secreted rhfib and chain complexes was investigated in the
highest expressing mice in order to evaluate if the mammary gland can perform necessary
posttranslational modifications without limitation. The Aa-subunit of hfib has a punitive N-linked
glycosylation site Asn269 and Asn400 (Rixon et al., 1983), but it is not glycosylated in fully

assembled hfib. Deglycosylation experiments were performed to identify if Aa-subunit remains
deglycosylated when secreted by both monogenic and trigenic mice with results presented in
Figure 4. No band shifting was observed when human standard was digested with the enzymes
Endoglycosidase H (high mannose, Endo-H) or Glycopeptidase (high mannose or complex,
PNGase) that cleave N-linked saccharides. Upon treatment of trigenic prepared whey and
monogenic prepared whey with these enzymes, shifting of the Aa-subunit was not observed. This
suggests that the punitive site is not recognized by mammary epithelia following a similar pattern
to that of the liver.
The Bβ -chain of hfib is glycosylated with the carbohydrate side chain being in the
complexed form. Glycosylation of the Bβ -subunit is not required for secretion of assembled
fibrinogen, as cells treated with tunicamycin still can secrete fibrinogen (Yu, 1983). To evaluate
if the secreted Bβ -subunit is glycosylated when no other fibrinogen chains are present,
deglycosylation experiments were performed on monogenic prepared whey with results shown in
Figure 5a. As expected, no band shifting is observed with human standard when treated with
Endo-H, but

Figure 4. Glycosylation analysis of Aa-chain from WAP6FibAαand WAP6FibT.C. mouse prepared
whey. Prepared whey (l μl) from both monogenic and trigenic lines and hfib standard (230 ng) was
subjected to deglycosylation with either Endoglycosidase H (Endo-H, recognizing high mannose) or
Glycopeptidase (PNGase, cleaving both high mannose and complex structures) with resulting products run
on SDS -PAGE and probed with the Aa-chain AB784 polyclonal antibody. Aα= fibrinogen Aα-chain, N.T. =
non-transgenic prepared whey ( l μl).

fibrinogen standard does shift with PNGase treatment. Some shifting of the secreted Bβ subunit is
observed with Endo-H treatment, suggesting that some portions of the secreted Bβ chains are of
the high mannose type. Unfortunately, exact quantification can not be performed as the Bβ
subunit of murine fibrinogen migrates at the same rate, but it was observed that all of the rhfib Bβ

-subunit is glycosylated as shown by shifting of all material by PNGase. This suggests that
mammary epithelial cells can recognize the glycosylation site of rhfib Bβ chains when produced
without the other fibrinogen chains and core glycosylation does occur. In this case, the processing
ability of the mammary epithelial cell appears to be limiting, resulting in secretion of both high
mannose and complex saccharide glycosylated Bβ

subunits. Limitations in Bβ

chain

glycosylation are not restricted to mammary epithelia as it has been observed with transfected
COS-1 cells that a fractional amount of Bβ subunits in secreted rhfib was Endo-H sensitive. To
evaluate the amount of Endo-H sensitive Bβ subunits that are present in mammary epitheliaderived rhfib, similar deglycosylation experiments were performed on trigenic prepared whey.
Treatment of prepared whey derived from the

Figure 5. Glycosylation analysis of Bβ -chain from WAP6Fib Bβ 1 and WAP6T.C. prepared mouse
whey. Panel a, prepared whey ( 1 μ l) from a WAP6FiBβ b1 monogenic line and hfib standard (200 ng) was
subjected to deglycosylation with either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase) with
resulting products run on SDS-PAGE and probed with the Bβ -chain AB 785 polyclonal antibody. Note the

partial shifting of the Bβ -chain produced by Endo-H digestion of monogenic whey. Panel b, prepared whey
(1 μl) from a high expressing WAP6FibT.C. (line 37, homozygous) mouse and hfib standard (300 ng) was
subjected to deglycosylation with Endo-H and PNGase, separation and probing with AB 785 polyclonal
antibody. Note the majority of Bβ -chain is sensitive to Endo-H in the high expression whey. Panel c,
prepared whey (1μ l) from a medium expressing WAP6FibT.C. (line 10) mouse which is similar in
expression to the monogenic in panel a, and hfib standard (230 ng) was subjected to deglycosylation with
Endo-H and PNGase, separation and probing with AB 785 polyclonal antibody. Note the lack of sensitivity
to Endo-H in the expressed whey. N.T. ¼ non-transgenic.

highest expressing line with Endo-H (Figure 5b) resulted in shifting of all recombinant Bβ
chains to the deglycosylated state indicating that all assembled Bβ -chain was in the immature
form. In contrast, when rhfib was secreted at lower levels in milk as with line 10 mice, the Bβ chain was not susceptible to Endo-H treatment (Figure 5c). These observations suggest a rate
limitation for β-chain glycosylation when it is incorporated into fully assembled fibrinogen.
Several cell types have demonstrated the ability to N-glycosylate the°Cchains of assembled hfib
with saccharides complex in structure. To determine the glycosylation state of the γ-chain when
expressed without the a-or β-chain , prepared whey from WAP6Fibc1 mice was subjected to
deglycosylation experiments (Figure 6). Hfib standard did not shift when treated with Endo-H,
but did show a faster mobility when treated with PNGase. Mammary epithelia derived°Cchains
were not aﬀected by Endo-H treatment, but did shift under PNGase treatment. This observation
indicates that the γ-chain can be recognized by glycosylation pathways in mammary epithelia
when only the γ-chain is present and does not require association with the other chains for
glycosylation to occur. When the same experiment is performed on trigenic mouse prepared
whey derived from line 37, a small fraction of the°Cchains became deglycosylated under Endo-H
treatment, suggesting a subpopulation of immature°Cchains is able to be secreted. Thus, when
total fibrinogen and fibrinogen chain complexes are secreted by mammary epithelia into milk at
concentrations approaching 700 μg/ml, the ability of mammary epithelia to glycosylate properly
is compromised.
The functionality of assembled fibrinogen was assessed by first partially purifying the
recombinant fibrinogen away from the endogenous mouse fibrinogen which typically occurs in
milk and can be variable due to plasma passover from injury that can occur during milking. We
adapted aZn2+-dependent solubility based purification process used for isolating proteins from
transgenic milk (Degener et al., 1998) that discriminates between mouse and hfib (Butler et al.,

1997). After removal of the bulk of the caseins by ion exchange chromatography, the ion
exchange eluate was rendered with ZnCl (8 mM) to precipitate mouse fibrinogen. After treatment

Figure 6. Glycosylation analysis of γ-chain from WAP6Fibc1 and WAP6T.C. prepared mouse whey. Panel a,
prepared whey (1 μl) from a WAP6Fibc1 monogenic line and hfib standard (230 ng) was subjected to
deglycosylation with either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase) with resulting products run
on SDS -PAGE and probed with the Chemicon γ-chain antibody. Note the lack of shifting under Endo-H conditions
with the monogenic whey. Panel b, prepared whey from a WAP6FibT.C. (line 37, homozygous) mouse and hfib (230
ng) was subjected to deglycosylation treatment by either Endoglycosidase H (Endo-H) or Glycopeptidase (PNGase)
and separated by SDS-PAGE under reducing conditions then probed with the γ-chain Chemicon antibody. Note the
partial shifting of the°Cband upon Endo-H treatment of WAP6FibT.C. mouse whey. N.T. ¼ non-transgenic mouse
whey (1 μl).

with thrombin, the supernatant containing the soluble human transgenic hfib was shown to form a
visible clot-like precipitate similar to that of the human reference sample. The clot density of the
precipitate was found to increase after treatment with Factor XIII. No clots were formed with
supernatants analogously derived from control mouse milk. Western analysis of these reaction
mixtures containing human plasma derived fibrinogen (Figure 7a) and transgenic hfib (Figure 7b)
showed the disappearance of the γ-chain (lane 3 of panel a and panel b; human

Figure 7. Functional activity of recombinant fibrinogen. Recombinant fibrinogen was purified as listed in materials
and methods and subjected to thrombin activation and factor XIII cross linking along with human standard.
Products were denatured then separated by SDS-PAGE followed by probing with polyclonal AB786 antibody. Panel
a: lane 1, hfib without thrombin or factor XIII treatment; lane 2, hfib treated with thrombin; lane 3, hfib treated with
thrombin and factor XIII. Panel b: lane 1, purified recombinant without thrombin or factor XIII; lane 2 recombinant
with thrombin; lane 3, recombinant treated with both thrombin and factor XIII.°C °Crepresents the γ-chain –γchain crosslink.

and transgenic hfib, respectively) and the appearance of a species at an Mr of approximately 90
KDa after treatment with thrombin and Factor XIII. Western blot analysis specific to γ-chain
confirmed the 90 KDa species to be a c–c crosslinked product arising from the thrombin-Factor
XIII enzymatic reaction (data not shown). As reported previously (Prunkard et al., 1996), we
found evidence of c-glutamyl transferase activity in the milk mixtures leading to the formation of
c–c cross-linked chains even without the presence of human Factor XIII after thrombin treatment.
4.0 Discussion
The use of transgenic livestock as bioreactors to produce pharmaceutical biologics is
maturing with several derived proteins in or about to enter clinical trials (Drohan and Clark,
2000). New biologics are being discovered and brought forward as potential candidates for being
produced by the transgenic mammary gland, requiring rapid evaluation of both synthesis rate and
functionality. Transgenic mice oﬀer this platform for evaluation due to their short generation
intervals and ease of genetic manipulation, thus allowing production of a biologic before
investigation in larger animals. In contrast to previous studies using immortalized cell lines, we
have sought greater understanding of the relationship between the extent of glycosylation and
assembly of individual chains in the context of the healthy native physiology of the transgenic
mammary gland. Previous studies with fibrinogen secreted into the milk of transgenic mice
(Prunkard et al., 1996) did not focus upon glycosylation or secretion limits of individual chains in
relationship to assembly of functional mature fibrinogen.
In this report, we established lines of transgenic mice to study the genetic stability and
transmission characteristics of each transgene integration site and to develop both protein and

RNA expression profiles for each unique locus. When embryos were microinjected with an equal
molar ratio of DNA constructs, the resulting oﬀspring had both balanced and unbalanced ratios
incorporated into the genome. This observation is similar to a previous report (Burdon et al.,
1991) where three diﬀerent transgenes consisting of slightly modified mouse WAP genomic
sequences were co-injected resulting in highly imbalanced loci with regards to the three mouse
lines analyzed. We performed a detailed analysis of mRNA expression for each fibrinogen gene
in the WAP6FibT.C. loci (data not presented) and observed concert expression of each gene with
regards to copy number within the locus and that expression of the locus varied over the course
of lactation depending upon the line studied. This suggests that the 4.1 kbp mWAP promoter is
heavily influenced by elements flanking the integration site similar to the 2.4 mWAP promoter
and that the additional promoter sequences do not aﬀord insulation from these outlying elements
(McKnight et al., 1995). However, when the 4.1 kbp promoter is not inhibited by outlying
repressive elements, it can drive expression of fibrinogen cDNA to suﬃcient levels where protein
expression is approximately the same as when fibrinogen genomic coding elements are used such
as with the 4.2 kbp BLG promoter (Prunkard et al., 1996). Indeed, we show here that the 4.1 kbp
mWAP promoter can be used to independently express each fibrinogen subunit so as to result in
the assembly of fully functionally fibrinogen capable of forming a cross-linked clot.
While our primary goal is to evaluate the capacity of transgenic livestock as bioreactors to
produce rhfib in milk, the mammary gland provides a novel system from which to study
intracellular processing, assembly and secretion in a pathway which diﬀers from most
transformed cell lines. For example, the expression of rhfib in mammary epithelial cells of
transgenic mice should provide a naturally less restrictive traﬃcking environment due to the
nutritional role of most milk proteins. This was especially reflected by the unassembled b-rhfib
chain as well as other partially assembled rhfib complexes which were secreted into the milk. We
have previously shown that mammary epithelial tissue of transgenic mice can perform complex
post-translational processing at cell synthesis rates of greater than about 1–10 pg/cell/day
(Velander et al., 1992) and these recombinant protein synthesis rates are similar to that found in
previous rhfib cell culture studies (Yu et al., 1984; Danishefsky et al., 1990; Hartwig &
Danishefsky, 1991; Roy et al., 1994). Due to the high cell density of the mammary tissue relative
to cell culture, the expression levels in milk resulting from cDNA rhfib constructs under the
control of the 4.1 kb mWAP promoter were about 100–700 μg/ml total rhfib species. Fully

assembled rhfib was about 200 μg/ml of the total secreted rhfib species, indicating secretory
permissiveness in the case of assembly limitations. From this standpoint, the study of secreted
rhfib chains and complexes is more easily done in milk than in cell culture media.
Perhaps the biggest diﬀerence between mammary gland and cell culture expression was
with respect to secretion of free Bβ -chain; the milk of Bβ -monogenic mice showed free Bβ chain, while previously no cell line has been shown to secrete Bβ -chain alone. For example, the
secretion of immature rhfib and free hfib chains in COS-1, CHO, BHK, and HepG2 cell lines
showed a lack of detectable, free Bβ -chain (Danishefsky et al., 1990; Roy et al., 1994). This
occurred in both Bβ -chain only and Aa,Bβ ,γ-chain transfected cell lines indicating a higher
retention selectivity for Bβ -chain by the secretory pathway in these cells. Xia and Readman
(2001) have demonstrated in HepG2 and COS cells that the intracellular levels of each fibrinogen
chain are modulated by chain association to the degradation pathway proteins Sec61b (Bβ -chain)
and Hsp70 (Aαand γ-chain s). Their observations coupled with those we observed with the Bβ
chain secretion by Bβ -monogenic mice have allowed us to postulate that mammary epithelia has
a less restrictive secretory pathway as compared to cell culture lines studied so far.
We observed that the secretion of free β-chain could occur at 100 μg/ml in monogenic
mice, which is similar to the levels of the secreted free a (150 μg/ml) and°C(50 μg/ml) hfib
chains in the respective monogenic mouse lineages. The glycosylation of the secreted free βchain occurring in monogenic β-chain mouse milk was estimated to be about 30% high mannose
core. However, when secreted at similar levels in assembled hfib, the β-chain contained about
95% Endo-H sensitive carbohydrate which is similar to that found in assembled rhfib from COS1 cells. It is possible that the co-expression of a and c-rhfib chains with β-chain and/or the
assembly process occurring in trigenic mice can lower the eﬃciency of glycosylation processing
of the nascent β-chain . Since there was no free β-chain species detected in the milk of trigenic
rhfib mice, it is unlikely that β-chain s having high mannose core were kinetically unsuitable for
rhfib assembly.
Free a-chain was expressed in milk at the highest levels of the monogenic lineages and
represented as much as 10% of the total hfib species present in the milk of trigenic lineages. In
addition, Aα–c complexes were found at significant levels in the milks of trigenic lineages and
represented as much as about 30% of the rhfib species as detected by Western analysis. Thus, the
trafficking leading to secretion of Aα-only and Aα- chain containing complexes including mature
rhfib was eﬃcient in mammary tissue and similar to other non-epithelial cell types (Danishefsky

et al., 1990; Roy et al., 1994). In contrast to β-chain , γ-chain was found to have no Endo-H
sensitivity in freely secreted γ-chain from monogenic or assembled γ-chain in rhfib from
trigenic lineages. Thus, in mammary epithelial cells the trafficking and γ-chain assembly into
rhfib appears to be largely independent of glycosylation. The relative molecular weight of about
150 kDa of the a–c containing complexes would be consistent with an a–c–c complex as has been
postulated to occur in other cell types. Similarly to a-chain, no free γ-chain was detected in the
milk of trigenic lineages indicating that intracellular γ-chain was not pooled in excess relative to
the a-chain.
In summary, we have used the less restrictive secretory pathway of the mouse mammary
epithelia to express individual chains of a complex multimeric protein to be secreted to enable
glycosylation patterns to be studied.
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